Veradermics is trading at $144.37, up +4.03% in pre-market ahead of its scheduled investor call to review topline results from Part B of its Phase 3 Study 302 of VDPHL01. - The call is scheduled for 8:00 a.m. ET on November 9 and had not begun at the 7:30 a.m. alert time. - Broad market sentiment was also positive, but the pending clinical update is the clearest specific context for the move.